Adjuvant Sintilimab with or without Anti-VEGF Therapy After Resection in Hepatocellular Carcinoma with Microvascular Invasion: A Multicenter Retrospective Study
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Yi-Tao Zheng, Yun-Feng Shan, Shu-Qun Cheng · 2025
Read Adjuvant Sintilimab with or without Anti-VEGF Therapy After Resection in Hepatocellular Carcinoma with Microvascular Invasion: A Multicenter Retrospective Study by Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Yi-Tao Zheng, Yun-Feng Shan, Shu-Qun Cheng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717793.txt.
Description
Kang Wang and co-authors studied extra drug treatment after liver cancer surgery in two thousand twenty-five. Patients whose tumors invaded tiny vessels face high relapse risk after resection. The team asked whether an immune drug, alone or with a vessel-blocking drug, improves outcomes.
They reviewed one hundred seventy patients from three Chinese centers treated in two thousand twenty-two. Groups got observation, the immune drug sintilimab, or sintilimab plus anti-VEGF therapy. Relapse or death occurred in about sixty-one percent of the observation group, versus about forty-one percent in each drug group. Median relapse-free time nearly doubled with either drug plan. Added vessel therapy gave no clear extra gain, so it may not be needed for all.
Catalog record
| CREATOR | Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Yi-Tao Zheng, Yun-Feng Shan, Shu-Qun Cheng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |